Why thrombin PAR1 receptors are important to the cardiac surgical patient

Journal of Extra-Corporeal Technology

Volumn 39, Issue 4, 2007, Pages 305-307

  Landis, Clive ^a  

^a UNIVERSITY OF THE WEST INDIES   (Jamaica)

Author keywords

Antagonist; Cardiac surgery; Receptor; Thrombin

Indexed keywords

APROTININ; PLASMIN; PROTEINASE ACTIVATED RECEPTOR 1; PROTEINASE ACTIVATED RECEPTOR 1 ANTAGONIST; THROMBIN; THROMBIN RECEPTOR; UNCLASSIFIED DRUG; ANTIFIBRINOLYTIC AGENT; LIPOPROTEIN; LIPOPROTEIN-ASSOCIATED COAGULATION INHIBITOR; PROTEINASE ACTIVATED RECEPTOR; TISSUE FACTOR PATHWAY INHIBITOR;

ANTIINFLAMMATORY ACTIVITY; BLOOD CLOTTING; CLINICAL TRIAL; CONFERENCE PAPER; DRUG MECHANISM; DRUG MEGADOSE; DRUG SAFETY; DRUG USE; HEART SURGERY; HEMOSTASIS; HUMAN; POSTOPERATIVE COMPLICATION; PROTEIN FUNCTION; STROKE; THROMBOCYTE; THROMBOCYTE ACTIVATION; THROMBOSIS; VASCULAR ENDOTHELIUM; CARDIOPULMONARY BYPASS; DRUG ANTAGONISM; ENDOTHELIUM; METHODOLOGY; REVIEW; THORAX SURGERY;

ANTIFIBRINOLYTIC AGENTS; APROTININ; CARDIOPULMONARY BYPASS; ENDOTHELIUM; HUMANS; LIPOPROTEINS; RECEPTOR, PAR-1; RECEPTORS, PROTEINASE-ACTIVATED; THORACIC SURGERY; THROMBIN;

EID: 40949152481     PISSN: 00221058     EISSN: 29698960     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (20)

1. Vu T-KH, Hung DT, Wheaton VI, Coughlin SR. Molecular cloning of a functional thrombin receptor reveals a novel proteolytic mechanism of receptor activation. Cell. 1991;64:1057-68.
2. Vu T-KH, Wheaton VI, Hung DT, Charo I, Coughlin SR. Domains specifying thrombin-receptor interaction. Nature. 1991;353:674-7.
3. Parry MA, Myles T, Tschopp J, Stone SR. Cleavage of the thrombin receptor: identification of potential activators and inactivators. Biochem J. 1996;320:335-41.
4. Landis RC. Protease activated receptors: clinical relevance to hemostasis and inflammation. Hematol Oncol Clin North Am. 2007;21:103-13.
5. Oikonomopoulou K, Hansen KK, Saifeddine M, et al. Proteinase-activated receptors, targets for kallikrein signaling. J Biol Chem. 2006;281:32095-112.
6. Derian CK, Maryanoff BE, Zhang HC, Andrade-Gordon P. Therapeutic potential of protease-activated receptor-1 antagonists. Expert Opin Investig Drugs. 2003;12:209-21.
7. Moliterno DJ. Results of a Multinational Randomized, Double-Blind, Placebo-Controlled Study of a Novel Thrombin Receptor Antagonist SCH 530348 in Percutaneous Coronary Intervention. American College of Cardiology Meeting, New Orleans, LA, March 24, 2007.
8. Andrade-Gordon P, Maryanoff BE, Derian CK, et al. Design, synthesis, and biological characterization of a peptide-mimetic antagonist for a tethered-ligand receptor. Proc Natl Acad Sci USA. 1999;96:12257-62.
9. Royston D, Bidstrup BP, Taylor KM, Sapsford RN. Effect of aprotinin on need for blood transfusion after repeat open-heart surgery. Lancet. 1987;2:1289-91.
10. van Oeveren W, Jansen NJ, Bidstrup BP, et al. Effects of aprotinin on hemostatic mechanisms during cardiopulmonary bypass. Ann Thorac Surg. 1987;44:640-5.
11. Mohr R, Goor DA, Lusky A, Lavee J. Aprotinin prevents cardiopulmonary bypass-induced platelet dysfunction. A scanning electron microscope study. Circulation. 1992;86:II405-9.
12. Ferraris VA, Ferraris SP, Singh A, et al. The platelet thrombin receptor and postoperative bleeding. Ann Thorac Surg. 1998;65:352-8.
13. Alderman EL, Levy JH, Rich JB, et al. Analyses of coronary graft patency after aprotinin use: Results from the International Multicenter Aprotinin Graft Patency Experience (IMAGE) trial. J Thorac Cardiovasc Surg. 1998;116:716-30.
14. Poullis M, Manning R, Laffan M, Haskard DO, Taylor KM, Landis RC. The antithrombotic effect of aprotinin: Actions mediated via the proteaseactivated receptor 1. J Thorac Cardiovasc Surg. 2000;120:370-8.
15. Day JR, Punjabi PP, Randi AM, Haskard DO, Landis RC, Taylor KM. Clinical inhibition of the seven-transmembrane thrombin receptor (PAR1) by intravenous aprotinin during cardiothoracic surgery. Circulation. 2004;110:2597-600.
16. Khan TA, Bianchi C, Voisine P, Sandmeyer J, Feng J, Sellke FW. Aprotinin inhibits protease-dependent platelet aggregation and thrombosis. Ann Thorac Surg. 2005;79:1545-50.
17. Poston RS, White C, Gu J, et al. Aprotinin shows both hemostatic and antithrombotic effects during off-pump coronary artery bypass grafting. Ann Thorac Surg. 2006;81:104-10.
18. Sedrakyan A, Treasure T, Elefteriades JA. Effect of aprotinin on clinical outcomes in coronary artery bypass graft surgery: A systematic review and meta-analysis of randomized clinical trials. J Thorac Cardiovasc Surg. 2004;128:442-8.
19. Jurk K, Jahn UR, Van AH, et al. Platelets in patients with acute ischemic stroke are exhausted and refractory to thrombin, due to cleavage of the seven-transmembrane thrombin receptor (PAR-1). Thromb Haemost. 2004;91:334-44.
20. Day JRS, Taylor KM, Lidington EA, et al. Aprotinin inhibits proinflammatory activation of endothelial cells by thrombin through the protease-activated receptor 1. J Thorac Cardiovasc Surg. 2006;131:21-7.